Erectile Dysfunction in Patients with Multiple Chronic Conditions: A Cross- Sectional Study.


Journal

Endocrine, metabolic & immune disorders drug targets
ISSN: 2212-3873
Titre abrégé: Endocr Metab Immune Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269157

Informations de publication

Date de publication:
2023
Historique:
received: 04 11 2021
revised: 29 03 2022
accepted: 04 04 2022
pubmed: 27 5 2022
medline: 17 3 2023
entrez: 26 5 2022
Statut: ppublish

Résumé

The prevalence of erectile dysfunction (ED) rises with the number and severity of chronic diseases. This cross-sectional study assessed the frequency and severity of ED in patients with multiple chronic conditions. The 5-item International Index of Erectile Function questionnaire (IIEF-5) was used to diagnose and classify ED. The Charlson Comorbidity Index (CCI) was used to assess the burden of chronic comorbidity. The primary outcome was to assess the ED frequency according to CCI severity. The secondary outcomes included the assessment of the correlation between 1) IIEF-5 and total testosterone (TT), 2) CCI and TT, and 3) IIEF-5 and CCI. Lastly, the CCI and modified CCI (mCCI) performances were compared with each other. The overall frequency of ED increased along with the CCI score severity: 45% for CCI=0; 95% for CCI=1; 91% for CCI=2; 99% for CCI≥3 (p<.0001). CCI correlated negatively with TT levels and IIEF-5 score (r=-0.34 and -0.44; p<.0001). Compared to the CCI, a novel proposed mCCI performs well. The frequency and severity of ED are relevant in outpatients with sexual complaints and those with chronic comorbidities. Despite limitations, mCCI may be considered a reliable tool to assess the overall burden of multiple chronic conditions in patients with comorbidities. ED is a reliable proxy of overall male health. Further studies are needed to confirm this potential application.

Sections du résumé

BACKGROUND BACKGROUND
The prevalence of erectile dysfunction (ED) rises with the number and severity of chronic diseases.
AIMS OBJECTIVE
This cross-sectional study assessed the frequency and severity of ED in patients with multiple chronic conditions.
METHODS METHODS
The 5-item International Index of Erectile Function questionnaire (IIEF-5) was used to diagnose and classify ED. The Charlson Comorbidity Index (CCI) was used to assess the burden of chronic comorbidity. The primary outcome was to assess the ED frequency according to CCI severity. The secondary outcomes included the assessment of the correlation between 1) IIEF-5 and total testosterone (TT), 2) CCI and TT, and 3) IIEF-5 and CCI. Lastly, the CCI and modified CCI (mCCI) performances were compared with each other.
RESULTS RESULTS
The overall frequency of ED increased along with the CCI score severity: 45% for CCI=0; 95% for CCI=1; 91% for CCI=2; 99% for CCI≥3 (p<.0001). CCI correlated negatively with TT levels and IIEF-5 score (r=-0.34 and -0.44; p<.0001). Compared to the CCI, a novel proposed mCCI performs well.
DISCUSSION CONCLUSIONS
The frequency and severity of ED are relevant in outpatients with sexual complaints and those with chronic comorbidities. Despite limitations, mCCI may be considered a reliable tool to assess the overall burden of multiple chronic conditions in patients with comorbidities.
CONCLUSION CONCLUSIONS
ED is a reliable proxy of overall male health. Further studies are needed to confirm this potential application.

Identifiants

pubmed: 35616670
pii: EMIDDT-EPUB-123862
doi: 10.2174/1871530322666220523130212
doi:

Substances chimiques

Testosterone 3XMK78S47O

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

396-404

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Giuseppe Lisco (G)

Section of Internal Medicine, Geriatrics, Endocrinology, and Rare Disease, Interdisciplinary Department of Medicine, University of Bari, School of Medicine, Policlinico, Bari, Italy.

Nicola Bartolomeo (N)

Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy.

Maria Isabella Ramunni (MI)

Outpatients Clinic of Endocrinology and Metabolic Disease, Conversano Hospital, Bari, Italy.

Anna De Tullio (A)

Section of Internal Medicine, Geriatrics, Endocrinology, and Rare Disease, Interdisciplinary Department of Medicine, University of Bari, School of Medicine, Policlinico, Bari, Italy.

Matteo Domenico Carbone (MD)

Institute of Clinical and Hormonal Research, Foggia, Italy.

Edoardo Guastamcchia (E)

Section of Internal Medicine, Geriatrics, Endocrinology, and Rare Disease, Interdisciplinary Department of Medicine, University of Bari, School of Medicine, Policlinico, Bari, Italy.

Giovanni De Pergola (G)

Scientific Direction, Research Hospital, National Institute of Gastroenterology "Saverio de Bellis", Castellana Grotte, Bari, Italy.

Vincenzo Triggiani (V)

Section of Internal Medicine, Geriatrics, Endocrinology, and Rare Disease, Interdisciplinary Department of Medicine, University of Bari, School of Medicine, Policlinico, Bari, Italy.

Vito Angelo Giagulli (VA)

Section of Internal Medicine, Geriatrics, Endocrinology, and Rare Disease, Interdisciplinary Department of Medicine, University of Bari, School of Medicine, Policlinico, Bari, Italy.
Outpatients Clinic of Endocrinology and Metabolic Disease, Conversano Hospital, Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH